Jenburkt Pharmaceuticals Ltd.
JENBURPH
Jenburkt Pharmaceuticals Ltd.
JENBURPH
Jenburkt Pharmaceuticals Ltd. Share Price
1,048.00 +15.20 (+1.47%)Fundamentals
Market Cap₹455Cr | EPS₹78.70 |
Book Value/Share₹459.81 | P/E Ratio (TTM)13.88 |
Industry P/E (TTM)45.66 | P/B Ratio2.31 |
Long Term D/E0.01 | ROE18.83% |
Dividend Yield (TTM)0.00% | Sector P/E Ratio (TTM)41.98 |
Sector P/B Ratio5.79 |
Analysis
Overview
Key stock indicators that show how well a company is doing, making it easier to understand its true value and performance.
Outperformer
Highly Undervalued
Poor Quality
Low Price Fluctuation
Peer Comparison
Peer comparison lists companies from the same sector, scored and ranked based on Crisp Analysis. It helps understand how a company stands against its competitors.
Shareholding Pattern
Shareholding pattern shows how a company’s shares (ownership) are distributed among different shareholding entities like promoters, Foreign Institutional Investors (FIIs), Domestic Institutional Investors (DIIs), and retail investors, among others. Changes in the shareholding pattern can indicate the performance outlook of a stock.
FAQs on Jenburkt Pharmaceuticals Ltd.
The share price of Jenburkt Pharmaceuticals Ltd. is ₹1,048.00 on NSE as of 29/8/2026, 12:13:27 am. Share prices may change frequently due to market movements.
The market capitalisation of Jenburkt Pharmaceuticals Ltd. is ₹455Cr as of 29/8/2026, 12:13:27 am
The current Price to Earnings (P/E) ratio of Jenburkt Pharmaceuticals Ltd. is 13.88 as of 29/8/2026, 12:13:27 am
The Price to Book (P/B) ratio of Jenburkt Pharmaceuticals Ltd. stands at 2.31 as of 29/8/2026, 12:13:27 am
Jenburkt Pharmaceuticals Ltd. reported an ROE of 18.84% for the last reported financial year on a consolidated account basis.
As of 29/8/2026, 12:13:27 am, Jenburkt Pharmaceuticals Ltd.’s shareholding pattern is: promoters hold 46.60%, FIIs hold 0.00%, DIIs hold 0.10%, and public shareholders hold 53.30%.
The 52-week high of Jenburkt Pharmaceuticals Ltd. is ₹1,055.00 and the 52-week low is ₹1,030.10 as of 29/8/2026, 12:13:27 am.
The earnings per share (EPS) of Jenburkt Pharmaceuticals Ltd. is ₹13.34 for the quarter ended Jun 2026.
The stock symbol of Jenburkt Pharmaceuticals Ltd. is JENBURPH.
You can buy Jenburkt Pharmaceuticals Ltd. shares by opening a demat and trading account with Share.Market and placing a buy order on NSE or BSE during market hours.
The fair value of Jenburkt Pharmaceuticals Ltd. depends on factors such as earnings growth, financial performance, and overall market conditions. Investors should assess fundamentals before making investment decisions.
Earnings Per Share
Earnings per share (EPS) measures the profit earned by a company for each of its outstanding shares. Generally, the higher a company’s EPS is, the more profitable it is considered to be.
Income Statement
Also called a profit and loss statement, an income statement shows a company’s income, expenses, and how much profit or loss it has made over a specific accounting period. It provides a clear view of how well the business is running.
| Particulars (in Cr) | Jun 2026 | Q/Q Change |
|---|---|---|
| Operating Revenue | 35.51 | -20.43% |
| Other Income | 1.51 | -65.29% |
| Total Income | 37.03 | -24.40% |
| Total Expenditure | 29.49 | -2.93% |
| EBIDT | 7.54 | -48.53% |
| Depreciation | 0.64 | -20.99% |
| Interest | 0.13 | 0.00% |
| Tax | 0.88 | -69.23% |
| Net Profit | 5.89 | -45.71% |
Balance Sheet
A balance sheet is a financial statement that details a company’s assets, liabilities, and shareholders’ equity at a given time. It helps assess how financially strong and stable the company is.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Total Current Assets | 95.09 |
| Total Non-Current Assets | 130.92 |
| Fixed assets | 65.58 |
| Total Assets | 226.01 |
| Total Current liabilities | 23.15 |
| Total Non Current Liabilities | 5.83 |
| Total Equity Plus Liabilities | 226.01 |
| Total Shareholder Funds | 197.04 |
| Total Debt to Equity | 0.00% |
Cash Flow
Cash flow highlights the cash or cash equivalents moving in and out of a company during a particular period. It provides a clear picture of how well a company manages its cash by tracking its operating, investing and financing activities.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Cash from Operating Activity | 26.52 |
| Cash from Financing Activities | -8.86 |
| Cash from Investing Activities | -19.45 |
| Net Cash Flow | -1.79 |
Time Period: Daily
SMA/EMA (Moving Average) Analysis
Bullish Moving Averages0
Bearish Moving Averages16
5 Day
1,043.0010 Day
1,047.8020 Day
1,067.8030 Day
1,070.5050 Day
1,088.80100 Day
1,101.00150 Day
1,077.20200 Day
1,092.50Indicators
RSI (14)
39.60MACD (12, 26)
-14.23MACD Signal Line (9)
-13.06MFI (14)
66.53ATR (14)
31.48ADX (14)
16.57ROC (21)
-2.78ROC (125)
2.49Pivot Analysis
Pivot analysis uses a special price point, called the pivot point, to show the overall market trend during different periods. This pivot point is the average of the previous day’s high, low, and closing prices of a specific asset.
| Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 1,058.30 | 1,086.05 | 1,102.20 | 1,042.15 | 1,014.40 | 998.25 | 970.50 |
Note: Support and Resistance level for the day, calculated based on price range of the previous trading day.
Volume Analysis
Volume analysis tracks how many shares were traded for a specific period. Total traded volume represents the overall number of shares traded, while combined delivery volume indicates only those shares which are delivered (transferred for ownership). Delivered shares indicate long-term investor interest.
Earnings Per Share
Earnings per share (EPS) measures the profit earned by a company for each of its outstanding shares. Generally, the higher a company’s EPS is, the more profitable it is considered to be.
Income Statement
Also called a profit and loss statement, an income statement shows a company’s income, expenses, and how much profit or loss it has made over a specific accounting period. It provides a clear view of how well the business is running.
| Particulars (in Cr) | Jun 2026 | Q/Q Change |
|---|---|---|
| Operating Revenue | 35.51 | -20.43% |
| Other Income | 1.51 | -65.29% |
| Total Income | 37.03 | -24.40% |
| Total Expenditure | 29.49 | -2.93% |
| EBIDT | 7.54 | -48.53% |
| Depreciation | 0.64 | -20.99% |
| Interest | 0.13 | 0.00% |
| Tax | 0.88 | -69.23% |
| Net Profit | 5.89 | -45.71% |
Balance Sheet
A balance sheet is a financial statement that details a company’s assets, liabilities, and shareholders’ equity at a given time. It helps assess how financially strong and stable the company is.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Total Current Assets | 95.09 |
| Total Non-Current Assets | 130.92 |
| Fixed assets | 65.58 |
| Total Assets | 226.01 |
| Total Current liabilities | 23.15 |
| Total Non Current Liabilities | 5.83 |
| Total Equity Plus Liabilities | 226.01 |
| Total Shareholder Funds | 197.04 |
| Total Debt to Equity | 0.00% |
Cash Flow
Cash flow highlights the cash or cash equivalents moving in and out of a company during a particular period. It provides a clear picture of how well a company manages its cash by tracking its operating, investing and financing activities.
| Particulars (in Cr) | Mar 2026 |
|---|---|
| Cash from Operating Activity | 26.52 |
| Cash from Financing Activities | -8.86 |
| Cash from Investing Activities | -19.45 |
| Net Cash Flow | -1.79 |
Jenburkt Pharmaceuticals Ltd.
JENBURPH
Open Price | 1,031.00 |
Prev Close | 1,032.80 |
Upper Circuit | 1,214.50 |
Lower Circuit | 809.70 |
Volume | 501 |
Average Traded Price | 1,046.78 |
Historical Performance
| 1 Day | NA |
| 5 Days | NA |
| 1 Month | NA |
| 3 Months | NA |
| 1 Year | NA |
| 5 Years | NA |
| 10 Years | NA |